What is a biparametric prostate MRI and in which clinical situations should it be used?

Biparametric Prostate MRI: Definition and Clinical Applications

Biparametric MRI (bpMRI) is a streamlined prostate imaging technique that uses only T2-weighted and diffusion-weighted sequences (omitting the contrast-enhanced DCE sequence), and it is now proven noninferior to multiparametric MRI for detecting clinically significant prostate cancer while offering substantial advantages in cost, scan time, and patient safety.

What is Biparametric MRI?

Biparametric MRI is an abbreviated prostate MRI protocol that includes:

• T2-weighted imaging (T2WI) - provides anatomical detail
• Diffusion-weighted imaging (DWI) - detects areas of restricted diffusion characteristic of cancer

It deliberately excludes dynamic contrast-enhanced (DCE) imaging, which requires intravenous gadolinium contrast administration.

Evidence Supporting Biparametric MRI

The most compelling evidence comes from the 2025 PRIME trial 1, a prospective multicenter study of 490 biopsy-naive men across 22 centers in 12 countries. This landmark study demonstrated that bpMRI detected clinically significant prostate cancer in 29.2% of men compared to 29.6% with multiparametric MRI (difference -0.4%, meeting noninferiority criteria). Critically, 99% of scans were of adequate diagnostic quality, and bpMRI detected similar rates of clinically insignificant cancer (9.2% vs 9.6%).

A concurrent 2025 international observer study 2 with 62 readers from 45 centers across 20 countries evaluated 400 cases and found bpMRI noninferior to mpMRI with an AUROC of 0.853 vs 0.859 (difference -0.6%). At PI-RADS ≥3 threshold, sensitivity was 88.6% vs 89.4% and specificity was 58.6% vs 57.7%. Importantly, decision curve analysis showed bpMRI provided greater net benefit in biopsy-averse scenarios, while mpMRI showed benefit only in highly cancer-averse scenarios.

A 2025 meta-analysis 3 of 19 studies with 5,075 patients confirmed pooled sensitivity of 0.89, specificity of 0.73, and AUC of 0.90 for bpMRI in detecting clinically significant prostate cancer.

Clinical Situations for Biparametric MRI Use

Biopsy-Naive Patients

Based on the PRIME trial 1, bpMRI should be considered the new standard of care for initial prostate cancer diagnosis in men with elevated PSA or abnormal digital rectal examination. The 2017 ACR Appropriateness Criteria 4 support MRI-targeted biopsy as an appropriate option for biopsy-naive patients when suspicious lesions are identified.

Prior Negative Biopsy

The 2015 NCCN guidelines 5 specifically recommend that multiparametric MRI (and by extension, the noninferior bpMRI) should be considered in selected cases of men with at least 1 negative biopsy to identify regions of cancer missed on previous biopsies. Studies show cancer detection rates of 34-51% in this population using targeted biopsies 5.

Active Surveillance

The 2024 PRECISE v2 guidelines 6 provide a framework for serial MRI monitoring in active surveillance patients, though they note "robust data on the use of repeat MRI in active surveillance are lacking." The 2017 ACR guidelines 4 support using MRI to look for visible disease as a potential biopsy target in men on active surveillance.

Advantages of Biparametric MRI

Practical Benefits:

• Shorter scan time - approximately 15-20 minutes vs 30-45 minutes for mpMRI
• Lower cost - eliminates gadolinium contrast expense
• No contrast-related risks - avoids gadolinium toxicity, nephrogenic systemic fibrosis risk, and contraindications in renal impairment
• Increased scanner throughput - with approximately 4 million prostate MRIs performed globally annually, bpMRI could substantially increase capacity 1
• Better patient tolerance - shorter examination time

Critical Caveats and Limitations

Image Quality is Paramount

The NCCN guidelines 5 emphasize "the need for high-quality MRI and for radiologic expertise for optimal reading of scans." The success of bpMRI depends entirely on adequate technical quality - the PRIME trial's 99% adequate quality rate was achieved in specialized centers 1.

Not for Initial Biopsy Decision

The 2015 NCCN guidelines 5 explicitly state that "MRI alone should not be used to decide whether to perform biopsy" and "a negative MRI is not an indication to forego biopsy in a man with indications for first-time biopsy." Using MRI to exclude men from biopsies may miss up to 12% of significant cancers. All men with indications for biopsy should receive standard 12-core TRUS-guided biopsy regardless of MRI results.

PI-RADS 3 Lesions Remain Problematic

The 2019 PI-RADS steering committee 7 acknowledges ongoing challenges with equivocal lesions. The 2025 observer study 2 found that mpMRI increased sensitivity at alternative risk thresholds but at the expense of reduced specificity, particularly relevant for PI-RADS 3 lesions.

Reader Expertise Matters

The 2025 observer study 2 found that DCE imaging provided limited additional benefit for nonexpert readers, suggesting bpMRI may be particularly suitable when expert genitourinary radiologists are not available.

Practical Implementation Algorithm

For biopsy-naive patients with elevated PSA (>3 ng/mL) or abnormal DRE:

1. Perform bpMRI with high-quality T2WI and DWI sequences
2. If PI-RADS 1-2: Consider standard 12-core systematic biopsy based on other risk factors (PSA density, family history, race)
3. If PI-RADS 3-5: Perform MRI-targeted biopsy PLUS standard 12-core systematic biopsy
4. Never omit systematic biopsy based solely on negative MRI

For patients with prior negative biopsy and persistent suspicion:

1. Perform bpMRI to identify previously missed lesions
2. If suspicious lesions identified: MRI-targeted biopsy with or without systematic cores
3. If no lesions and high-risk features persist: Consider saturation biopsy or transperineal approach 5

For active surveillance patients:

1. Baseline bpMRI at diagnosis
2. Serial bpMRI at 12-month intervals minimum 6
3. Report changes using PRECISE v2 scoring system
4. Significant change = >50% volume increase, increased conspicuity, or progression to T3a 6

Future Directions

The 2019 PI-RADS steering committee 7 notes that "mpMRI has been incorporated into multiple clinical care guidelines, mostly in the clinical setting of prior negative biopsy," but widespread adoption for biopsy-naive men "has yet to appear widely in internationally urologic guidelines." The 2025 PRIME trial 1 provides the high-quality prospective data needed to change this paradigm, potentially establishing bpMRI as the new standard of care globally.